The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.

Zobair M YounossiMaria StepanovaSean FelixThomas JeffersElena YounossiZachary GoodmanAndrei RacilaBrian P LamLinda Henry

Published in: Alimentary pharmacology & therapeutics (2023)

The combination of ELF and FIB-4 may provide practitioners with easily obtained information to risk stratify patients with NAFLD who could be referred to specialists or for enrollment in clinical trials.

Keyphrases

liver fibrosis
clinical trial
primary care
health insurance
health information
healthcare
randomized controlled trial
general practice
social media